Dr. Ragon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000
Summary
- Dr. Brittany Ragon is a hematologist/medical oncologist in Charlotte, NC. She received her medical degree from University of South Carolina School of Medicine, trained at Vanderbilt University Medical Center and the MD Anderson Cancer Center, and has been in practice 8 years. She specializes in hematologic oncology and cellular therapy and is experienced in leukemia, stem cell transplantation, myeloproliferative disorders, myelodysplastic syndromes, and clinical informatics.
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
- Vanderbilt University Medical CenterResidency, Internal Medicine, 2011 - 2014
- University of South Carolina School of MedicineClass of 2011
- Clemson UniversityBS, Biosystems Engineering, Minor Bioengineering, Summa Cum Laude, 2003 - 2007
Certifications & Licensure
- NC State Medical License 2017 - 2025
- TX State Medical License 2015 - 2018
- TN State Medical License 2013 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha Honor Society Junior AOA, 2010
- Algernon Sydney Sullivan Award 2007
- Calhoun Scholar—Awarded B.C. Inabinet Honors Medallion 2007
- Join now to see all
Clinical Trials
- Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Start of enrollment: 2021 May 20
- Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia Start of enrollment: 2022 Apr 05
Publications & Presentations
PubMed
- 20 citationsFinancial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy.Thomas G Knight, Melissa Aguiar, Myra Robinson, Allison Morse, Tommy Chen
JCO Oncology Practice. 2022-09-01 - 39 citationsMinimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.Brittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, Farhad Ravandi, Jorge E. Cortes
American Journal of Hematology. 2017-06-09 - 39 citationsPenetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE NetworkCarlos J. Gallego, Amber A. Burt, Agnes S. Sundaresan, Zi Ye, Christopher G. Shaw
American Journal of Human Genetics. 2015-10-01
Journal Articles
- Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasRagon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNar..., American Journal of Hematology, 9/27/2016
- Geographic distance is not associated with inferior outcome when using long-term transplant clinic strategyRagon BK, Clifton C, Chen H, Savani B, Englehardt B, Kassim A, Jagasia M, Bio Blood and Marrow Transplant., 1/1/2014
- Penetrance of Hemochromatosis in HFE Genotypes Resulting in pCys282Tyr and p[Cys282Tyr];[His63Asp] in the eMERGE NetworkGallego C, Burt A, Sundaresan A, Shaw C, Crosslin D, Crane P, Fullerton S, Hansen K, Carrell D, Kuivaniemi H, Derr K, Zi Y, Andrade M, McCarty C, Kitchner T, Ragon BK,..., Am J Hum Genet., 1/1./2015
- Join now to see all
Abstracts/Posters
- BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)Brittany K Ragon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Patient Reported Financial Toxicity in Myeloproliferative NeoplasmsBrittany K Ragon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Network based proteomic profiling of leukemia and myelodysplasia defines protein expression signatures and suggests targeted therapy combinations.Kornblau S, Hu C, Hoff F, Ragon BK, Qiu Y, Zhang N, Yoo SY, Coombes K, Horton T, Qutub A, Global Reverse Phase Protein Array Workshop, 1/1/2016
- Join now to see all
Lectures
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukemia.Houston, TX - 1/1/2016
- Amyloidosis: “X” marks the spot.Houston, TX - 1/1/2015
- TPMT DeficiencyHouston, TX - 1/1/2015
- Join now to see all
Press Mentions
- Levine Cancer Institute Specializes Atrium's Hospital-at-Home Model - Charlotte Business JournalMarch 30th, 2021
- Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MDJanuary 24th, 2024
Grant Support
- Leukemia Research Foundation New Investigator GrantLeukemia Research Foundation2018–2019
- NIH T32 Training GrantNIH2015–2017
Professional Memberships
- Member
- Member
- American Society of Transplantation and Cellular TherapyMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: